Mitochondria as targets in angiogenesis inhibition.
Angiogenesis is integral to the growth and metastatic spread of tumours, and its targeting is an effective anti-tumour strategy. Currently hundreds of anti-angiogenic therapeutics exist in varying stages of development, a number of which have recently gained US Food and Drug Administration (FDA) approval for the treatment of various human cancers. One class of anti-angiogenic agents directly inhibit endothelial cell function and induce endothelial cell death so as to prevent their integration into new blood vessels. The mitochondria are the focal point for a variety of pro-apoptotic signals, and this review highlights those anti-angiogenic agents that involve the mitochondria in the execution of endothelial cell death. A brief overview of angiogenesis and the mitochondrial apoptotic pathway is also given.
Park
Danielle
D
Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney 2052, Australia.
Dilda
Pierre J
PJ
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D008928:Mitochondria / Q000187:drug effects*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology
D020533:Angiogenesis Inhibitors